Lupin Limited Share Price & Analysis
Price Chart
Fundamentals
Strengths
- ✓Excellent return on equity (ROE 29.1%)
- ✓Efficient capital deployment (ROCE 30.3%)
- ✓Attractively valued vs sector (P/E 17.9x vs industry 48.9x)
- ✓Low debt relative to equity (D/E 0.3x)
Peer Comparison
| Company | CMP | Mkt Cap | P/E | P/B | ROE % | ROCE % | D/E |
|---|---|---|---|---|---|---|---|
| SUNPHARMA Sun Pharmaceutical Industries Limited | ₹1,783 | ₹4.3L Cr | 34.4 | 5.12 | 16 | 20.5 | 0.07 |
| DIVISLAB Divi's Laboratories Limited | ₹6,616 | ₹1.7L Cr | 66.1 | 10.48 | 16.5 | 22 | 0.01 |
| TORNTPHARM Torrent Pharmaceuticals Limited | ₹4,416 | ₹1.5L Cr | 66.4 | 17.81 | 27.6 | 15.4 | 0.33 |
| APOLLOHOSP Apollo Hospitals Enterprise Limited | ₹8,315 | ₹1.2L Cr | 59.5 | 12.62 | 22.1 | 17.9 | 0.88 |
| CIPLA Cipla Limited | ₹1,402 | ₹1.1L Cr | 27.3 | 3.29 | 12.4 | 16.6 | 0.01 |
| ZYDUSLIFE Zydus Lifesciences Limited | ₹1,091 | ₹1.1L Cr | 20 | 4.05 | 21.2 | 21.2 | 0.38 |
| DRREDDY Dr. Reddy's Laboratories Limited | ₹1,283 | ₹1.1L Cr | 25.4 | 2.83 | 11.8 | 13.6 | 0.16 |
Showing 7 peers in the same sector · Sorted by market cap
Shareholding Pattern
LUPIN · as of Mar 2026
| Category | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Promoters | 47.04% | 47.01% | 46.99% | 46.96% | 46.94% | 46.91% |
| FII | 16.11% | 18.29% | 19.32% | 21.50% | 22.04% | 21.46% |
| DII | 29.72% | 27.76% | 26.77% | 25.10% | 24.73% | 25.41% |
| Public | 7.10% | 6.93% | 6.92% | 6.44% | 6.27% | 6.21% |
| Govt | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% |
Corporate Events
To consider and approve the Audited Standalone and Consolidated Financial Results of the Company for the quarter and year ended March 31, 2026, and recommend dividend, if any.
Dividend - Rs 12 Per Share
Dividend - Rs 8 Per Share
Dividend - Rs 4 Per Share
Latest News
All news →NATCO Pharma, Lupin get USFDA approval for cancer drug
*NATCO Pharma, Lupin get USFDA approval for Eribulin Mesylate injection.* This greenlight allows both firms to launch a generic version of the cancer drug in the US market. The approval is expected to drive near-term revenue via market exclusivity. 📊 *STOCKS:* NATCOPHARM, LUPIN | 🏢 *SECTOR:* Pharma | #MEDIUMIMPACT #USFDA
Lupin gets FDA nod for famotidine injection.
*Lupin gets FDA nod for famotidine injection.* The company received U.S. FDA approval for its generic famotidine injection, USP, strengthening its hospital products portfolio. This approval allows Lupin to launch the injectable anti-ulcer drug in the U.S. market. The product had **$**120 million** in annual sales** in the U.S. over the past 12 months. 📊 *STOCKS:* LUPIN | 🏢 *SECTOR:* Pharma | #MEDIUMIMPACT #FDAApproval
Lupin gets U.S. FDA nod for new drug
*Lupin gets U.S. FDA nod for new drug.* The company has received approval for Glycerol Phenylbutyrate Oral Liquid, used in urea cycle disorder treatment. This expands Lupin’s presence in the U.S. specialty market. The drug had **$28 million** in U.S. sales over the past year. 📊 *STOCKS:* LUPIN | 🏢 *SECTOR:* Pharma | #MEDIUMIMPACT #FDAApproval
Lupin receives EIR from US FDA for Goa facility
*Lupin receives EIR from US FDA for its Goa facility.* The **EIR (Establishment Inspection Report)** signifies successful completion of FDA inspection at the facility, validating manufacturing practices and quality standards. This regulatory clearance strengthens Lupin's operational credibility in the US market and supports continued product registrations from this site. 📊 *STOCKS:* LUPIN | 🏢 *SECTOR:* Pharma | #MEDIUMIMPACT #FDA
Financials
Quarterly Results
| Metric | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹7.2K Cr ▲1.7% | ₹7.0K Cr ▲12.4% | ₹6.3K Cr ▲10.6% | ₹5.7K Cr ▼1.8% | ₹5.8K Cr ▲1.7% | ₹5.7K Cr ▲1.3% | ₹5.6K Cr ▲12.9% | ₹5.0K Cr |
| Op. Profit | ₹2.3K Cr ▼3.4% | ₹2.3K Cr ▲35.6% | ₹1.7K Cr ▲30.7% | ₹1.3K Cr ▼2.6% | ₹1.4K Cr ▲1.2% | ₹1.3K Cr ▲8.0% | ₹1.2K Cr ▲24.5% | ₹997 Cr |
| OPM | 32.0% ▼3.0% | 33.0% ▲17.9% | 28.0% ▲21.7% | 23.0% ▼4.2% | 24.0% ▲0.0% | 24.0% ▲9.1% | 22.0% ▲10.0% | 20.0% |
| Net Profit | ₹1.2K Cr ▼20.5% | ₹1.5K Cr ▲21.6% | ₹1.2K Cr ▲56.1% | ₹782 Cr ▼9.0% | ₹859 Cr ▲0.0% | ₹859 Cr ▲6.6% | ₹806 Cr ▲119.0% | ₹368 Cr |
| EPS (₹) | 25.73 ▼20.5% | 32.36 ▲21.2% | 26.69 ▲57.7% | 16.92 ▼9.7% | 18.74 ▲0.3% | 18.69 ▲6.3% | 17.58 ▲122.8% | 7.89 |
Values in ₹ Cr · Source: Screener.in
Annual Profit & Loss
| Metric | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ₹28.0K Cr ▲23.1% | ₹22.7K Cr ▲13.5% | ₹20.0K Cr ▲20.2% | ₹16.6K Cr ▲1.4% | ₹16.4K Cr ▲8.2% | ₹15.2K Cr ▼1.4% | ₹15.4K Cr ▲4.8% | ₹14.7K Cr ▼7.2% | ₹15.8K Cr ▼9.0% | ₹17.4K Cr |
| Expenses | ₹19.1K Cr ▲9.8% | ₹17.4K Cr ▲7.5% | ₹16.2K Cr ▲8.6% | ₹14.9K Cr ▼7.8% | ₹16.2K Cr ▲28.5% | ₹12.6K Cr ▼3.3% | ₹13.0K Cr ▲7.6% | ₹12.1K Cr ▼4.3% | ₹12.6K Cr ▼1.7% | ₹12.9K Cr |
| Op. Profit | ₹8.8K Cr ▲67.0% | ₹5.3K Cr ▲38.9% | ₹3.8K Cr ▲120.8% | ₹1.7K Cr ▲685.8% | ₹219 Cr ▼91.5% | ₹2.6K Cr ▲9.0% | ₹2.4K Cr ▼8.0% | ₹2.6K Cr ▼18.6% | ₹3.1K Cr ▼30.1% | ₹4.5K Cr |
| OPM | 32.0% ▲39.1% | 23.0% ▲21.1% | 19.0% ▲90.0% | 10.0% ▲900.0% | 1.0% ▼94.1% | 17.0% ▲13.3% | 15.0% ▼11.8% | 17.0% ▼15.0% | 20.0% ▼23.1% | 26.0% |
| Other Income | ₹-133 Cr ▼165.8% | ₹202 Cr ▲54.2% | ₹131 Cr ▼13.2% | ₹151 Cr ▼28.1% | ₹210 Cr ▲52.2% | ₹138 Cr ▲203.0% | ₹-134 Cr ▼247.3% | ₹91 Cr ▲106.9% | ₹-1.3K Cr ▼1335.8% | ₹106 Cr |
| Interest | ₹434 Cr ▲47.1% | ₹295 Cr ▼5.4% | ₹312 Cr ▲13.9% | ₹274 Cr ▲91.6% | ₹143 Cr ▲1.4% | ₹141 Cr ▼61.2% | ₹363 Cr ▲20.2% | ₹302 Cr ▲48.0% | ₹204 Cr ▲33.3% | ₹153 Cr |
| Depreciation | ₹1.4K Cr ▲17.7% | ₹1.2K Cr ▼2.3% | ₹1.2K Cr ▲35.9% | ₹881 Cr ▼46.9% | ₹1.7K Cr ▲87.0% | ₹887 Cr ▼8.6% | ₹970 Cr ▲14.7% | ₹846 Cr ▼22.1% | ₹1.1K Cr ▲19.1% | ₹912 Cr |
| PBT | ₹6.9K Cr ▲71.2% | ₹4.0K Cr ▲65.8% | ₹2.4K Cr ▲238.3% | ₹716 Cr ▲152.2% | ₹-1.4K Cr ▼181.9% | ₹1.7K Cr ▲89.0% | ₹887 Cr ▼41.0% | ₹1.5K Cr ▲174.8% | ₹547 Cr ▼84.6% | ₹3.5K Cr |
| Tax % | 22.0% ▲22.2% | 18.0% ▼10.0% | 20.0% ▼47.4% | 38.0% ▲280.0% | 10.0% ▼63.0% | 27.0% ▼79.2% | 130.0% ▲120.3% | 59.0% ▲11.3% | 53.0% ▲89.3% | 28.0% |
| Net Profit | ₹5.4K Cr ▲62.0% | ₹3.3K Cr ▲70.8% | ₹1.9K Cr ▲332.1% | ₹448 Cr ▲129.3% | ₹-1.5K Cr ▼224.4% | ₹1.2K Cr ▲554.8% | ₹-270 Cr ▼143.9% | ₹615 Cr ▲138.4% | ₹258 Cr ▼89.9% | ₹2.6K Cr |
| EPS (₹) | 116.65 ▲62.3% | 71.88 ▲71.1% | 42.01 ▲344.6% | 9.45 ▲128.1% | -33.62 ▼225.4% | 26.81 ▲550.6% | -5.95 ▼144.4% | 13.4 ▲141.0% | 5.56 ▼90.2% | 56.63 |
| Div Payout | 15.0% ▼11.8% | 17.0% ▼10.5% | 19.0% ▼54.8% | 42.0% ▲450.0% | -12.0% ▼150.0% | 24.0% ▲123.8% | -101.0% ▼373.0% | 37.0% ▼58.9% | 90.0% ▲592.3% | 13.0% |
Values in ₹ Cr · Source: Screener.in
Balance Sheet
| Item | Sep 2025 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Liabilities | ||||||||||
| Equity Capital | ₹91 Cr ▲0.0% | ₹91 Cr ▲0.0% | ₹91 Cr ▲0.0% | ₹91 Cr ▲0.0% | ₹91 Cr ▲0.0% | ₹91 Cr ▲0.0% | ₹91 Cr ▲1.1% | ₹90 Cr ▲0.0% | ₹90 Cr ▲0.0% | ₹90 Cr |
| Reserves | ₹19.5K Cr ▲14.2% | ₹17.1K Cr ▲20.5% | ₹14.2K Cr ▲14.7% | ₹12.4K Cr ▲2.6% | ₹12.1K Cr ▼12.0% | ₹13.7K Cr ▲10.2% | ₹12.4K Cr ▼8.8% | ₹13.7K Cr ▲1.2% | ₹13.5K Cr ▲0.6% | ₹13.4K Cr |
| Borrowings | ₹6.2K Cr ▲14.1% | ₹5.4K Cr ▲86.4% | ₹2.9K Cr ▼35.7% | ₹4.5K Cr ▲9.2% | ₹4.2K Cr ▼18.9% | ₹5.1K Cr ▼18.7% | ₹6.3K Cr ▼25.8% | ₹8.5K Cr ▲18.9% | ₹7.1K Cr ▼10.3% | ₹8.0K Cr |
| Other Liabilities | ₹7.7K Cr ▲20.9% | ₹6.3K Cr ▼3.2% | ₹6.5K Cr ▲12.9% | ₹5.8K Cr ▲8.5% | ₹5.3K Cr ▲18.7% | ₹4.5K Cr ▼24.6% | ₹6.0K Cr ▲10.0% | ₹5.4K Cr ▲2.3% | ₹5.3K Cr ▲11.6% | ₹4.7K Cr |
| Total Liabilities | ₹33.5K Cr ▲15.6% | ₹29.0K Cr ▲22.0% | ₹23.8K Cr ▲4.2% | ₹22.8K Cr ▲5.3% | ₹21.7K Cr ▼7.6% | ₹23.4K Cr ▼5.6% | ₹24.8K Cr ▼10.3% | ₹27.7K Cr ▲6.3% | ₹26.0K Cr ▼0.7% | ₹26.2K Cr |
| Assets | ||||||||||
| Fixed Assets | ₹10.3K Cr ▲5.5% | ₹9.7K Cr ▲9.5% | ₹8.9K Cr ▲6.3% | ₹8.4K Cr ▲13.2% | ₹7.4K Cr ▼6.3% | ₹7.9K Cr ▼0.7% | ₹7.9K Cr ▼28.4% | ₹11.1K Cr ▲7.0% | ₹10.4K Cr ▼6.1% | ₹11.0K Cr |
| CWIP | ₹593 Cr ▲14.7% | ₹517 Cr ▼33.1% | ₹773 Cr ▼37.6% | ₹1.2K Cr ▲8.0% | ₹1.1K Cr ▲7.5% | ₹1.1K Cr ▲13.4% | ₹940 Cr ▼42.7% | ₹1.6K Cr ▼36.9% | ₹2.6K Cr ▲21.8% | ₹2.1K Cr |
| Investments | ₹3.3K Cr ▲190.7% | ₹1.1K Cr ▲6.6% | ₹1.1K Cr ▲107.9% | ₹517 Cr ▼42.6% | ₹900 Cr ▼63.3% | ₹2.5K Cr ▲3.4% | ₹2.4K Cr ▲3.4% | ₹2.3K Cr ▲776.0% | ₹262 Cr ▼87.7% | ₹2.1K Cr |
| Other Assets | ₹19.3K Cr ▲9.8% | ₹17.6K Cr ▲35.1% | ₹13.0K Cr ▲2.6% | ₹12.7K Cr ▲3.8% | ₹12.2K Cr ▲1.6% | ₹12.0K Cr ▼11.3% | ₹13.6K Cr ▲7.3% | ₹12.6K Cr ▼1.2% | ₹12.8K Cr ▲17.3% | ₹10.9K Cr |
| Total Assets | ₹33.5K Cr ▲15.6% | ₹29.0K Cr ▲22.0% | ₹23.8K Cr ▲4.2% | ₹22.8K Cr ▲5.3% | ₹21.7K Cr ▼7.6% | ₹23.4K Cr ▼5.6% | ₹24.8K Cr ▼10.3% | ₹27.7K Cr ▲6.3% | ₹26.0K Cr ▼0.7% | ₹26.2K Cr |
Values in ₹ Cr · Source: Screener.in
Cash Flow Statement
| Item | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating CF | ₹3.0K Cr ▼17.8% | ₹3.6K Cr ▲92.3% | ₹1.9K Cr ▲416.9% | ₹367 Cr ▼79.9% | ₹1.8K Cr ▲24.0% | ₹1.5K Cr ▼11.8% | ₹1.7K Cr ▼4.9% | ₹1.8K Cr ▼57.4% | ₹4.1K Cr ▲1177.0% | ₹-382 Cr |
| Investing CF | ₹-4.2K Cr ▼143.7% | ₹-1.7K Cr ▼33.0% | ₹-1.3K Cr ▼199.6% | ₹1.3K Cr ▲204.2% | ₹-1.2K Cr ▼212.0% | ₹1.1K Cr ▲133.7% | ₹-3.3K Cr ▼798.3% | ₹470 Cr ▲118.6% | ₹-2.5K Cr ▲62.7% | ₹-6.8K Cr |
| Financing CF | ₹1.7K Cr ▲179.3% | ₹-2.2K Cr ▼548.1% | ₹-337 Cr ▲78.6% | ₹-1.6K Cr ▲16.6% | ₹-1.9K Cr ▼111.6% | ₹-891 Cr ▼219.8% | ₹744 Cr ▲149.9% | ₹-1.5K Cr ▼444.6% | ₹433 Cr ▼92.6% | ₹5.8K Cr |
| Net Cash Flow | ₹560 Cr ▲325.8% | ₹-248 Cr ▼190.8% | ₹273 Cr ▲213.8% | ₹87 Cr ▲106.7% | ₹-1.3K Cr ▼177.3% | ₹1.7K Cr ▲293.2% | ₹-872 Cr ▼219.6% | ₹729 Cr ▼63.9% | ₹2.0K Cr ▲253.5% | ₹-1.3K Cr |
| Free Cash Flow | ₹1.3K Cr ▼50.7% | ₹2.7K Cr ▲526.6% | ₹436 Cr ▲182.1% | ₹-531 Cr ▼146.2% | ₹1.1K Cr ▲44.1% | ₹798 Cr ▲13.0% | ₹706 Cr ▲170.5% | ₹261 Cr ▼82.7% | ₹1.5K Cr ▲124.5% | ₹-6.2K Cr |
Values in ₹ Cr · Source: Screener.in
Key Ratios History
| Metric | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 88d ▲2.3% | 86d ▼12.2% | 98d ▲3.2% | 95d ▼12.0% | 108d ▼16.3% | 129d ▲0.8% | 128d ▲6.7% | 120d ▲31.9% | 91d ▼21.6% | 116d |
| Inventory Days | 292d ▲7.4% | 272d ▲12.4% | 242d ▼7.3% | 261d ▼6.5% | 279d ▲20.3% | 232d ▼18.0% | 283d ▲11.9% | 253d ▼4.9% | 266d ▼3.6% | 276d |
| Days Payable | 158d ▼3.1% | 163d ▲19.9% | 136d ▲5.4% | 129d ▼5.8% | 137d ▼15.4% | 162d ▼12.0% | 184d ▲3.4% | 178d ▼5.8% | 189d ▲12.5% | 168d |
| Cash Conv. Cycle | 223d ▲14.4% | 195d ▼4.4% | 204d ▼10.1% | 227d ▼8.8% | 249d ▲25.1% | 199d ▼12.3% | 227d ▲16.4% | 195d ▲16.8% | 167d ▼25.8% | 225d |
| Working Capital Days | 58d ▲9.4% | 53d ▲65.6% | 32d ▼28.9% | 45d ▲32.4% | 34d ▲3.0% | 33d ▼71.3% | 115d ▼8.7% | 126d ▲100.0% | 63d ▼38.2% | 102d |
| ROCE | 21.0% ▲31.3% | 16.0% ▲166.7% | 6.0% ▲185.7% | -7.0% ▼177.8% | 9.0% ▲0.0% | 9.0% ▼10.0% | 10.0% ▲0.0% | 10.0% ▼47.4% | 19.0% ▼20.8% | 24.0% |
Source: Screener.in · Lower days = better efficiency
Deep Dive Analysis
About Lupin Limited
Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai. Lupin develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions.
Healthcare · Pharmaceuticals & Biotechnology